Sign In
Buy TOVX
$0.288
+0.0020 (+0.699%)
At Close: Jun 03, 2026
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
08:00am, Monday, 11'th Aug 2025
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress i
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results
08:40am, Wednesday, 14'th May 2025
- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial -
Theriva Biologics Announces Closing of $7.5 Million Public Offering
04:30pm, Thursday, 08'th May 2025
ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to
Theriva Biologics Announces Pricing of $7.5 Million Public Offering
09:17am, Wednesday, 07'th May 2025
ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to
Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) Interim blinded safety and phar
Theriva™ Biologics to Present at the 2025 NeauxCancer Conference
08:10am, Wednesday, 19'th Mar 2025
ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disease
Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results
04:10pm, Thursday, 06'th Mar 2025
– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 –
Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual
04:05pm, Wednesday, 05'th Mar 2025
ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disease
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
08:00am, Thursday, 05'th Dec 2024
ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases
ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat canc
Theriva Biologics Announces Pricing of $2.5 Million Public Offering
09:06pm, Thursday, 26'th Sep 2024
ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics desi
- Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain and the USA within 21 months –
Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program
08:00am, Monday, 16'th Sep 2024
Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies T
Theriva Biologics Announces Reverse Stock Split
04:05pm, Friday, 16'th Aug 2024
ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of hig
Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma
08:15am, Wednesday, 31'st Jul 2024
ROCKVILLE, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related di
